Comparative Pharmacology
Head-to-head clinical analysis: ASBRON versus OXTRIPHYLLINE PEDIATRIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ASBRON versus OXTRIPHYLLINE PEDIATRIC.
ASBRON vs OXTRIPHYLLINE PEDIATRIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Asbron is a combination product containing theophylline and guaifenesin. Theophylline is a methylxanthine that inhibits phosphodiesterase, leading to increased intracellular cAMP levels, resulting in bronchodilation and anti-inflammatory effects. Guaifenesin is an expectorant that increases respiratory tract fluid secretions to reduce mucus viscosity.
Xanthine derivative that inhibits phosphodiesterase, increasing cyclic AMP levels; antagonizes adenosine receptors, leading to bronchodilation, central nervous system stimulation, and positive inotropic effects.
1-2 tablets (130-260 mg theophylline equivalent) orally every 6-8 hours; maximum 6 tablets/day.
200 mg orally every 6-8 hours; extended-release: 400-600 mg orally every 12 hours.
None Documented
None Documented
4-6 hours in adults; prolonged to 8-12 hours in hepatic impairment or elderly patients
Neonates: 24-36 hours; Infants 1-6 months: 14-29 hours; Children 6-12 months: 9-18 hours; Children 1-9 years: 3-6 hours; Adults: 7-12 hours. Half-life prolonged in hepatic impairment, CHF, and COPD.
Primarily renal (70-80% as unchanged drug), biliary/fecal (~15-20% as metabolites and unchanged drug)
Renal (70-80% as unchanged drug, 10-15% as metabolites); biliary/fecal (<10%)
Category C
Category C
Bronchodilator
Bronchodilator